The Lancet Retracts 1977 Commentary That Declared Asbestos-Contaminated Talc Safe

For decades, the talc industry told consumers, regulators, and courts that cosmetic talc powder was safe—even when it contained asbestos. A key piece of that defense was a 1977 commentary published in The Lancet, one of the world’s most respected medical journals. Published as an unsigned editorial—a format that carried the implicit authority of the journal itself—it concluded that there was “no reason to believe” that cosmetic talc had caused cancer or lung disease.

That statement is now officially retracted.

The Lancet announced the retraction after historians David Rosner, Ph.D., and Gerald Markowitz, Ph.D., of Columbia University and the City University of New York, presented the journal with documentary evidence revealing that the commentary was written by Francis J C Roe—a cancer researcher who was also an undisclosed paid consultant to Johnson & Johnson, one of the world’s leading producers of cosmetic talc products.

The evidence goes further. According to the documents, Roe shared an advance draft of the commentary with Johnson & Johnson and revised it based on their feedback before submitting it to The Lancet. Gavin Hildick-Smith, J&J’s Medical Director at the time, wrote in a private internal memo that it is hoped that this editorial in a journal [that] gets worldwide distribution will help allay anxieties in government officials, physicians, and the public concerning the health hazard of cosmetic-grade talc.

If you or a loved one was diagnosed with mesothelioma or another asbestos-related disease after exposure to talcum powder, this retraction matters. It confirms what the evidence has shown for years: the assurances of safety were built on industry-corrupted science.

What The Lancet Retracted—and Why It Matters

The retracted commentary, titled “Cosmetic Talc Powder,” appeared in The Lancet on June 25, 1977. It dismissed concerns about asbestos contamination in talc products and praised the cosmetics industry’s self-regulation, specifically citing the Cosmetic, Toiletry and Fragrance Association (CTFA) and its British counterpart for having “drawn up specifications for cosmetic talc which ensure the virtual absence of fibrous amphiboles.”

In its Editors’ reply, The Lancet confirmed that its records show the editor at the time “had manually annotated an archived copy of the journal with the full name and address of the author, for the purpose of attributing payment.” The editors stated that Roe’s concealed relationship with Johnson & Johnson “was a clear breach of publishing ethics” and that “had the editors at the time known of this situation and been aware of the author’s undeclared competing interest, they would not have published this commentary.”

The implications are profound. An unsigned editorial in a premier medical journal carries enormous weight with regulators, courts, and the public. For nearly five decades, this commentary was treated as credible, independent science. It was neither.

The Industry Playbook: How Talc Manufacturers Manipulated the Science

The retraction does not exist in isolation. It fits a well-documented pattern of industry manipulation that historians, scientists, and litigators have been uncovering for years.

Ghostwriting in a Prestigious Journal

The Rosner and Markowitz letter, published alongside the retraction, details how the cosmetics industry sought to “influence public and medical discourse” as part of its campaign against regulation. An important part of this effort was “to promote positive notices in scientific journals that argued that cosmetic talc products were safe to use.” The 1977 Lancet commentary was the crown jewel of that strategy: an industry-written piece published under the journal’s own banner, with no disclosure of the author’s financial ties to J&J.

Manufacturing “Nondetected” Results

Markowitz and Rosner have documented in peer-reviewed research how the CTFA orchestrated a campaign to ensure that testing methods would fail to detect asbestos in talc. When independent laboratories found asbestos in consumer talc products in the mid-1970s, the industry did not remove the contamination. Instead, it developed its own testing method—the J4-1 method—which could only detect asbestos at levels above 0.5%, far less sensitive than the government’s method, which measured contamination down to 0.1% for amphibole asbestos and 0.01% for chrysotile. The U.S. government acquiesced to allowing the industry’s less sensitive method and remains in use today.

Blocking Federal Regulation for Half a Century

The FDA first attempted to regulate asbestos in cosmetic talc in the 1970s. The industry fought back through lobbying, public relations, and the strategic use of science. The 1977 Lancet commentary played a direct role in stalling those regulatory efforts. In December 2024, the FDA finally issued a proposed rule requiring standardized asbestos testing for talc cosmetics under the Modernization of Cosmetics Regulation Act (MoCRA). But on November 28, 2025, the FDA withdrew the proposal, leaving cosmetic talc testing unregulated once again.

Why This Retraction Matters Now

This retraction arrives at a critical moment for talc safety and accountability.

IARC Classified Talc as “Probably Carcinogenic”

In June 2024, the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, upgraded its classification of talc to Group 2A—“probably carcinogenic to humans.” This applies even to talc not containing asbestos, based on sufficient evidence in experimental animals and strong mechanistic evidence. Talc containing asbestos remains classified as Group 1—a known human carcinogen.

Tens of Thousands of Lawsuits Expose Industry Knowledge

As of early 2026, more than 90,000 lawsuits have been filed against Johnson & Johnson and other talc manufacturers. Internal documents produced in litigation have confirmed that companies knew about asbestos contamination as early as the 1970s but continued to market their products as safe. In December 2025, a Maryland jury awarded $1.5 billion to a woman who developed peritoneal mesothelioma after years of talc use. In October 2025,
a California jury awarded $966 million in a similar case. Defense lawyers in these cases have cited the 1977 Lancet commentary as evidence that the medical community considered talc safe—a citation that now carries a retraction notice.

The FDA Walked Away from Asbestos Testing

The November 2025 withdrawal of the FDA’s proposed asbestos testing rule means there is still no federal requirement that manufacturers test their talc cosmetics for asbestos contamination. The retraction of the very commentary that helped justify decades of industry self-regulation makes the absence of federal oversight all the more troubling.

What This Means for Mesothelioma Victims and Their Families

For people diagnosed with mesothelioma or ovarian cancer after exposure to talcum powder, this retraction matters for several important reasons:

• It removes a key defense exhibit. The 1977 commentary was presented by defendants in courtrooms across the country to argue that the scientific consensus supported product safety. That citation now carries a retraction confirming it was ghostwritten by a paid industry consultant.
• It validates decades of independent research. Scientists like Markowitz, Rosner, and others spent years documenting how the talc industry manipulated testing and publications. This retraction confirms their findings at the highest level of medical publishing.
• It strengthens ongoing and future claims. The retraction provides powerful evidence that the industry engaged in a coordinated, decades-long effort to deceive regulators, courts, and the public about the dangers of asbestos in talc.
• It underscores the urgency of acting within the statute of limitations. New Jersey and Pennsylvania have specific deadlines for filing asbestos-related claims. If you or a family member has been diagnosed, time matters.

The Scholars Who Helped Expose the Truth

David Rosner (Columbia University) and Gerald Markowitz (City University of New York) have spent decades investigating how industries manipulate science to protect profits at the expense of public health. Their published work on the talc industry, appearing in the American Journal of Public Health and other peer-reviewed journals, has been instrumental in documenting how companies suppressed evidence of asbestos contamination in consumer products.

On December 8, 2025, Rosner and Markowitz wrote to The Lancet presenting newly released documents from litigation discovery—now publicly available on toxicdocs.org—proving that the 1977 commentary was ghostwritten by Francis J C Roe, a paid J&J consultant. Their letter, published alongside the retraction in the March 25, 2026, issue, connects the retracted commentary to the broader documented history of industry interference in talc science.

As Rosner and Markowitz note, the industry’s opposition to regulation “gained legitimacy” when The Lancet published the unsigned commentary, and “over the nearly half-century since…millions of men, women, and children have been exposed to contaminated cosmetic talc.”

How Cohen, Placitella & Roth Can Help

At Cohen, Placitella & Roth, we have spent decades representing families affected by asbestos exposure—including those harmed by asbestos-contaminated talc products. We understand the science, the litigation history, and the corporate strategies that companies have used to deny responsibility.

If you or a loved one has been diagnosed with mesothelioma, ovarian cancer, lung cancer, or another asbestos-related disease after exposure to talcum powder, we are here to help. Our mesothelioma attorneys offer free, confidential evaluations to help you understand your legal options.

Disclaimer: This blog post is for informational purposes only and does not constitute legal or medical advice. Every case is different. If you have questions about your legal rights, please contact an attorney. Cohen, Placitella & Roth is a law firm licensed in New Jersey and Pennsylvania. Prior results do not guarantee a similar outcome.

Last updated: March 25, 2026. This post will be reviewed and updated as additional information becomes available.